Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Avidity Biosciences, Inc. (RNA) reported a Q3 loss of $0.65 per share, which was better than the Zacks Consensus Estimate of a $0.79 loss. However, the company lagged in revenue estimates.
November 08, 2024 | 12:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avidity Biosciences reported a Q3 loss of $0.65 per share, better than the expected $0.79 loss, but missed revenue estimates.
The company's EPS was better than expected, which is positive, but missing revenue estimates could offset this. The mixed results may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100